132 related articles for article (PubMed ID: 30575721)
1. Loss of Phd2 cooperates with BRAF
Liu S; Zhang G; Guo J; Chen X; Lei J; Ze K; Dong L; Dai X; Gao Y; Song D; Ecker BL; Yang R; Feltcher C; Peng K; Feng C; Chen H; Lee RX; Kerestes H; Niu J; Kumar S; Xu W; Zhang J; Wei Z; Martin JS; Liu X; Mills G; Lu Y; Guo W; Sun L; Zhang L; Weeraratna A; Herlyn M; Wei W; Lee FS; Xu X
Nat Commun; 2018 Dec; 9(1):5426. PubMed ID: 30575721
[TBL] [Abstract][Full Text] [Related]
2. RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.
Laugier F; Finet-Benyair A; André J; Rachakonda PS; Kumar R; Bensussan A; Dumaz N
Oncotarget; 2015 Sep; 6(29):28120-31. PubMed ID: 26356562
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism.
Sánchez-Hernández I; Baquero P; Calleros L; Chiloeches A
Cancer Lett; 2012 Jan; 314(2):244-55. PubMed ID: 22056813
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic Braf induces melanocyte senescence and melanoma in mice.
Dhomen N; Reis-Filho JS; da Rocha Dias S; Hayward R; Savage K; Delmas V; Larue L; Pritchard C; Marais R
Cancer Cell; 2009 Apr; 15(4):294-303. PubMed ID: 19345328
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.
Damsky W; Micevic G; Meeth K; Muthusamy V; Curley DP; Santhanakrishnan M; Erdelyi I; Platt JT; Huang L; Theodosakis N; Zaidi MR; Tighe S; Davies MA; Dankort D; McMahon M; Merlino G; Bardeesy N; Bosenberg M
Cancer Cell; 2015 Jan; 27(1):41-56. PubMed ID: 25584893
[TBL] [Abstract][Full Text] [Related]
6. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
[TBL] [Abstract][Full Text] [Related]
7. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE; You MJ; DePinho RA; McMahon M; Bosenberg M
Nat Genet; 2009 May; 41(5):544-52. PubMed ID: 19282848
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Role of Endothelial PHD2 in the Hepatic Steatosis.
Zhou LY; Zeng H; Wang S; Chen JX
Cell Physiol Biochem; 2018; 48(3):1003-1011. PubMed ID: 30036883
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
10. The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia.
Di Conza G; Trusso Cafarello S; Loroch S; Mennerich D; Deschoemaeker S; Di Matteo M; Ehling M; Gevaert K; Prenen H; Zahedi RP; Sickmann A; Kietzmann T; Moretti F; Mazzone M
Cell Rep; 2017 Feb; 18(7):1699-1712. PubMed ID: 28199842
[TBL] [Abstract][Full Text] [Related]
11. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
12. Inducible BRAF suppression models for melanoma tumorigenesis.
Hoeflich KP; Jaiswal B; Davis DP; Seshagiri S
Methods Enzymol; 2008; 439():25-38. PubMed ID: 18374154
[TBL] [Abstract][Full Text] [Related]
13. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.
Jiang L; Campagne C; Sundström E; Sousa P; Imran S; Seltenhammer M; Pielberg G; Olsson MJ; Egidy G; Andersson L; Golovko A
BMC Cancer; 2014 Nov; 14():857. PubMed ID: 25413220
[TBL] [Abstract][Full Text] [Related]
14. CDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.
McNeal AS; Liu K; Nakhate V; Natale CA; Duperret EK; Capell BC; Dentchev T; Berger SL; Herlyn M; Seykora JT; Ridky TW
Cancer Discov; 2015 Oct; 5(10):1072-85. PubMed ID: 26183406
[TBL] [Abstract][Full Text] [Related]
15. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
16. Sox2 is not required for melanomagenesis, melanoma growth and melanoma metastasis in vivo.
Cesarini V; Guida E; Todaro F; Di Agostino S; Tassinari V; Nicolis S; Favaro R; Caporali S; Lacal PM; Botti E; Costanzo A; Rossi P; Jannini EA; Dolci S
Oncogene; 2017 Aug; 36(31):4508-4515. PubMed ID: 28368402
[TBL] [Abstract][Full Text] [Related]
17. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.
Patton EE; Widlund HR; Kutok JL; Kopani KR; Amatruda JF; Murphey RD; Berghmans S; Mayhall EA; Traver D; Fletcher CD; Aster JC; Granter SR; Look AT; Lee C; Fisher DE; Zon LI
Curr Biol; 2005 Feb; 15(3):249-54. PubMed ID: 15694309
[TBL] [Abstract][Full Text] [Related]
19. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
Zingg D; Debbache J; Peña-Hernández R; Antunes AT; Schaefer SM; Cheng PF; Zimmerli D; Haeusel J; Calçada RR; Tuncer E; Zhang Y; Bossart R; Wong KK; Basler K; Dummer R; Santoro R; Levesque MP; Sommer L
Cancer Cell; 2018 Jul; 34(1):69-84.e14. PubMed ID: 30008323
[TBL] [Abstract][Full Text] [Related]
20. AKT1 Activation Promotes Development of Melanoma Metastases.
Cho JH; Robinson JP; Arave RA; Burnett WJ; Kircher DA; Chen G; Davies MA; Grossmann AH; VanBrocklin MW; McMahon M; Holmen SL
Cell Rep; 2015 Nov; 13(5):898-905. PubMed ID: 26565903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
